Full-Time

In Vitro Biologist/Molecular Pharmacologist

Confirmed live in the last 24 hours

Schrödinger

Schrödinger

501-1,000 employees

Computational platform for biopharmaceutical research

Government & Public Sector
Enterprise Software
Biotechnology

Compensation Overview

$120k - $180kAnnually

Mid, Senior

Cambridge, MA, USA + 1 more

More locations: New York, NY, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in molecular pharmacology, biochemistry, or a related field, with at least three years of experience in pharmaceutical or biotechnology industries
  • Extensive background in in vitro biology assay development and execution as it relates to HitID, LI, and LO phases of drug discovery
  • In-depth knowledge of protein biochemistry and enzymology and experience in biophysical techniques such as MST, SPR, and/or ITC desired
  • Experience managing external studies at CROs preferred
Responsibilities
  • Guide in vitro biology research strategies for exploratory and early-stage drug discovery efforts
  • Lead in vitro biology or molecular pharmacology for drug discovery programs and manage experimental design, development, and implementation of biochemical, biophysical, and cell-based assays for small molecule drug discovery projects
  • Oversee data review and analysis and interpretation of in vitro results
  • Independently manage CRO scientists to support, guide, and troubleshoot IVB assay development
  • Collaborate with other functional area experts on hit-finding activities in the undrugged target space
  • Participate in target evaluations, particularly tractability assessment

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. The platform offers advanced computational tools and services that help these organizations in their drug discovery processes. Schrödinger's products work by utilizing sophisticated algorithms and simulations to model molecular interactions, which can accelerate the identification of potential drug candidates. What sets Schrödinger apart from its competitors is its extensive experience since 1990 and its commitment to both independent and collaborative drug discovery programs across various therapeutic areas. The company's goal is to enhance scientific research and development through its platform, ultimately contributing to advancements in healthcare.

Company Stage

IPO

Total Funding

$362.7M

Headquarters

New York City, New York

Founded

1990

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • $19.5M Gates Foundation grant boosts platform for neglected diseases, expanding market reach.
  • Predictive toxicology tools initiative could lead to safer, efficient drug development.
  • SGR-1505 discovery showcases ability to reduce drug discovery timelines significantly.

What critics are saying

  • Recursion and Exscientia merger creates strong AI-driven drug discovery competitor.
  • Avicenna's independent expansion could lead to competitive tensions with Schrödinger.
  • High R&D costs may strain resources despite Gates Foundation's $10M grant.

What makes Schrödinger unique

  • Schrödinger's platform supports diverse clients, including biopharma, academia, and government labs.
  • The company excels in rapid drug discovery, exemplified by SGR-1505's swift development.
  • Schrödinger's collaboration with Avicenna enhances medicinal chemistry through machine learning.

Help us improve and share your feedback! Did you find this helpful?